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Abstract: Cutaneous melanoma circulating tumour cells (CTCs) are phenotypically and molecularly
heterogeneous. We profiled the gene expression of CTC subpopulations immunomagnetic-captured
by targeting either the melanoma-associated marker, MCSP, or the melanoma-initiating marker,
ABCB5. Firstly, the expression of a subset of melanoma genes was investigated by RT-PCR in
MCSP-enriched and ABCB5-enriched CTCs isolated from a total of 59 blood draws from 39 melanoma
cases. Of these, 6 MCSP- and 6 ABCB5-enriched CTC fractions were further analysed using a
genome-wide gene expression microarray. The transcriptional programs of both CTC subtypes
included cell survival maintenance, cell proliferation, and migration pathways. ABCB5-enriched
CTCs were specifically characterised by up-regulation of genes involved in epithelial to mesenchymal
transition (EMT), suggesting an invasive phenotype. These findings underscore the presence of at
least two distinct melanoma CTC subpopulations with distinct transcriptional programs, which may
have distinct roles in disease progression and response to therapy.
Keywords: circulating tumour cells; melanoma; ABCB5; MCSP; gene expression
1. Background
Metastatic melanoma is an aggressive tumour that is extremely difficult to treat, thought due
to the heterogenous nature of the tumours [1,2]. The isolation and study of circulating tumour cells
(CTCs) is an emerging field of basic and clinical cancer research worldwide. CTCs, released by all the
concurrent tumours within the patient, are responsible for the haematogenous spread of the cancer.
CTCs offer an accessible source to ascertain the biology of all tumours within the patient in real
time and provide a biomarker to anticipate clinical outcome and monitor treatment response in a
personalised manner [3,4], and perhaps a readout of the heterogeneity of melanoma tumours.
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In melanoma, CTCs have to date been shown to provide prognostic information and
evidence of treatment response in real time [5–9]. Melanoma CTCs are also known to be highly
heterogeneous [5,10–12] and to show differential response to treatment [5,8]. In fact, we have shown
that subpopulations of CTCs expressing the receptor activator of nuclear factor kappa B (RANK) and
the programmed death-ligand 1 (PD-L1) are associated with response to MAPK and PD-1 inhibitory
treatments, respectively [5,6]. More detailed phenotypic and molecular characterisation of CTCs is
hindered by the lack of a ubiquitous marker for CTC detection, as reviewed by Marsavela, et al. [13].
CTCs derived from epithelial cancers commonly express cytokeratin and/or EpCAM (epithelial cell
adhesion molecule) [14–16], which are used for CTC isolation and detection. By contrast, melanoma
CTCs do not commonly express these markers [17,18], since melanocytes originate from the neural
crest lineage [19,20]. Therefore, the isolation and detection of melanoma CTCs has to date relied on the
use of a variety of markers, not well formalised across the literature [5,9–12,21].
Conventionally, CTCs have been captured or detected by targeting the melanoma-associated
chondroitin sulphate proteoglycan (MCSP, HMW-MAA, CSPG4, NG2) [5,7–10,22–24]. This cell surface
proteoglycan, reported to be overexpressed in over 90% of melanoma tissue samples, is thought
to increase the tumorigenic potential of melanoma cells, by increasing cell proliferation, survival,
invasion, spreading, and migration [25,26]. However, we found in a previous study [5] that CTCs
more commonly express melanoma-initiating markers, such as the ATP-binding cassette sub-family B
member 5 (ABCB5) than melanoma-associated markers, such as MCSP. The transmembrane transporter
ABCB5 is associated with melanomagenesis, stem cell maintenance, metastasis, and treatment
resistance to MAPK inhibition [27–29]. Interestingly, we showed that ABCB5 is expressed only by
rare subpopulations within patient-matched tumour tissues [5], supporting the hypothesis that CTCs
are derived from rare subpopulations in the tumour with the potential to initiate metastases [28,30].
Taken together, it seems clear that cells positive for MCSP and ABCB5 represent two different CTC
subpopulations, yet there is no knowledge about the differential biology of these subpopulations.
To better understand the molecular diversity of CTC subpopulations and their role in melanoma
metastasis, we profiled the transcriptome of CTCs enriched immunomagnetically by targeting
MCSP or ABCB5, using firstly an RT-PCR assay involving a panel of five melanoma-specific genes,
then microarray genome-wide expression profiling. These approaches firstly identified the presence of
CTCs in the samples (five specific genes), then, using microarrays, we identified differentially expressed
genes and pathways in these two CTC subpopulations. Finally, we compared the transcriptomes
of these enriched cells to publicly available single cell RNAseq data from melanoma tumours [31],
to better understand the features of melanoma tumour cells that give rise to CTCs.
2. Results
2.1. Expression of Five Melanoma-Specific Transcripts in Immunomagnetically Enriched ABCB5 and MCSP
CTC Fractions from Metastatic Melanoma Patients
Fifty-nine blood samples from 39 metastatic melanoma patients were subjected to CTC enrichment
using immunomagnetic beads conjugated to anti-MCSP or anti-ABCB5 antibodies (Table 1).
Table 1. Demographic and clinical information of metastatic melanoma patients.
Characteristic n % of Total
Total patients enrolled 39
Age at enrolment (years)
Median (60)
Range (30–84)
Gender
Male 16 59%
Female 23 41%
Cancers 2019, 11, 157 3 of 15
Table 1. Cont.
Characteristic n % of Total
Stage of disease at baseline
Stage IV
M1a 5 13%
M1b 5 13%
M1c 19 49%
M1d 10 25%
Mutational status of tumour
BRAF Mut 26 67%
V600E * 20 51%
V600K 5 13%
V600R 1 3%
NRAS Mut 3 7%
Q61K 2 5%
Q61L 1 2%
BRAF/NRAS WT 10 26%
* One case with an additional BRAF S607F mutation.
Total RNA was isolated from the CTC fractions and molecularly characterised by assessing the
expression of a panel of five melanoma-specific genes by a sensitive RT-PCR assay. As previously
reported [12,32], this assay assessed the gene expression of melanoma specific genes, MLANA/MART-1
(melanoma antigen recognized by T cells), TYR (tyrosinase), MAGEA3 (melanoma antigen family A3),
PAX3 (paired box protein Pax-3 isoform 3), and ABCB5 at a sensitivity level of at least one melanoma
cell in a background of 1 × 105 WBCs. A total of 25 (42%) samples were found positive for CTCs
based on expression of any one of these transcripts in either of the CTC fractions enriched from their
blood. Of those, nine patients had detectable transcripts in both fractions, six were only positive in the
MCSP-enriched fraction, and 10 were only positive in the ABCB5-enriched fraction. This suggests that
CTCs can be isolated by targeting either MCSP or ABCB5 cell surface markers.
As illustrated in Figure 1, differential expression of the melanoma specific transcripts was observed
between and within CTC fractions enriched with MCSP- or ABCB5-coated beads, suggesting the
molecular heterogeneity of these two CTC subpopulations. In detail, MCSP-enriched CTCs were
characterised by a higher frequency of MLANA, TYR, and PAX3 and the exclusive expression of
MAGEA3 relative to ABCB5-enriched CTCs. On the other hand, the expression of ABCB5 was most
commonly detected in ABCB5-enriched CTC fraction, but no other genes were co-detected with ABCB5.
Conversely, in MCSP-enriched CTC fractions, ABCB5 transcripts were co-detected with TYR, PAX3,
MLANA or MAGEA3 transcripts in three CTC fractions, whilst five CTC fractions had exclusive ABCB5
expression, and the remaining expressed other melanocyte lineage genes (Figure 1). No expression of
these five genes was detected in MCSP- or ABCB5-enriched fractions derived from similarly evaluated
healthy donors (N = 16).
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Figure 1. Heterogeneity in gene expression of MCSP- and ABCB5-enriched circulating tumour
cell (CTC) fractions. Gene expression profiling of five melanoma-specific genes in CTC fractions
enriched with MCSP- (M) and ABCB5- (A) coated beads that were positive for any transcript (25 out of
59 samples). Heatmap represents the expression levels of the melanoma-associated genes MLANA,
TYR, MAGEA, ABCB5, and PAX3, which were assessed by qRT-PCR. All samples were positive for 18S
rRNA (not shown), used as endogenous control. Each heatmap square corresponds to a Ct value for
a target gene and a given sample; a higher tone of red indicates a higher gene expression and light
yellow indicates no transcripts detected. Unsupervised hierarchical clustering demonstrates the inter-
and intra- molecular heterogeneity of CTC subpopulations.
2.2. MCSP and ABCB5 CTC Subpopulations Exhibit Distinct Gene Expression Profiles
To further characterise the MCSP and ABCB5 CTCs, total RNA isolated from the dichotomised
CTC enriched fractions of six MCSP-enriched CTC samples and six ABCB5-enriched CTC samples
identified as RT-PCR positive for any of the five melanoma specific genes was further characterised
by whole genome expression microarray analysis. CTC samples were profiled and contrasted to the
same number of samples from six healthy control bloods enriched with either MCSP or ABCB5 coated
beads (Figure S1). Gene expression analysis identified 308 genes that were differentially expressed
between MCSP-enriched CTC fractions from metastatic melanoma patients and healthy controls.
From those, 260 and 48 genes were significantly up- or down-regulated, respectively (Table S1).
For ABCB5, 210 genes were differentially expressed in CTC fractions derived from melanoma patients
relative to those from controls, with 187 genes significantly up-regulated and 23 genes significantly
down-regulated (Table S2).
An unsupervised hierarchical clustering analysis successfully differentiated patient
immunomagnetic-enriched fractions from those of healthy control samples. Additionally,
this analysis partially clustered the enriched CTC fractions based on whether these were enriched
using MCSP or ABCB5 coated beads; two ABCB5-CTC fractions were the exception exhibiting very
distinct gene expression patterns (Figure 2A).
Comparison of the genes significantly up-regulated in MCSP- and ABCB5-enriched patient
fractions revealed differential gene expression patterns, with only 15 genes commonly up-regulated
by both MCSP and ABCB5 CTC fractions (Figure 2B and Table S3). A total of 245 genes were only
up-regulated in MCSP CTC fractions (Table S4) and 172 genes were only up-regulated in ABCB5 CTC
fractions (Table S5) relative to healthy controls, suggesting that MCSP and ABCB5 CTCs might be two
molecularly different cell types.
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Figure 2. MCSP and ABCB5 CTCs have distinctive gene expression patterns. (A) Unsupervised
hierarchical clustering analysis of differentially expressed genes between CTC fractions enriched from
samples of healthy donors (N = 6) and melanoma patients (N = 6) using immunomagnetic beads
targeting MCSP or ABCB5. Each row is a single gene and each column is a single sample. Red
indicated up-regulation and blue indicates down-regulation according to the colour scale at the bottom.
The squares indicate the genes that were up-regulated in melanomas (yellow box) and in controls (light
green box). Genes that are differentially expressed (with ANOVA p < 0.05 and fold difference 2 vs.
respective controls) in either cell type (MSCP or ABCB5 CTCs) were used to perform an unsupervised
hierarchical clustering. This analytical approach discriminated the gene expression patterns from
MCSP- (dark green box) and ABCB5-enriched (red box) CTC fractions. (B) Comparison of up-regulated
genes between MCSP- (green circle) and ABCB5-enriched (red circle) CTC fractions found only 15 genes
shared between these two CTC fractions.
2.3. Tumour Necrosis Factor Alpha (TNFA) Signalling and Epithelial Mesenchymal Transition (EMT) Are
Significantly Enriched in the MCSP and ABCB5 CTC Fractions, Respectively
To gain a better understanding of the role of these up-regulated genes in CTC subpopulations,
we performed gene set enrichment analyses (GSEA) of the up-regulated genes in the MCSP- or
ABCB5-enriched CTC fractions. This approach identified 10 distinctive hallmarks in each CTC subtype,
with the TNFα signalling being the most prominent in the MCSP-enriched fraction, whereas the EMT
hallmark was the most prominent in the ABCB5- fraction (Tables 2 and 3). Of note, the KRAS signalling
and the PI3K-AKT/mT ORC1 signalling hallmarks were found to be commonly enriched between the
MCSP- and ABCB5-enriched CTC fractions. However, the genes enriching these cellular hallmarks
differ for each CTC type. Specifically, M CSP CTCs were characterised by the enrichment of the
TNFA/NFKB, IL2/STAT5 and IL6/JAK/STAT3 signalling hallmarks. On the other hand, ABCB5 CTCs
were characterised by enrichment of the apical junction and EMT hallmarks (Figure 3).
2.4. In Silico Analysis Identifies Melanoma Cell-Associated Genes in the Gene Expression Profiles of the MCSP-
and ABCB5-Enriched CTC Fractions
To discern which of the genes found to be up-regulated in the MCSP- and ABCB5-enriched
CTC fractions were also preferentially expressed by single melanoma tumour cells, an in silico
analytical approach was performed using publicly available single cell RNAseq data from melanoma
tumours (GSE72056) [31]. Comparison of gene expression profiles of 1257 single melanoma cells and
3256 single nonmalignant cells from these tissues identified a total of 847 genes which were more
specifically expressed by single melanoma cells than by the nonmalignant cells (Figure 4 and Table S6).
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Subsequently, this list of melanoma-expressed genes was compared against the up-regulated genes in
the MCSP- and ABCB5-enriched CTC fractions.
Figure 3. MCSP- and ABCB5-enriched CTCs exhibit distinct transcriptional programming, with ABCB5
CTCs displaying an invasive phenotype. Schematic representation of cellular hallmarks enriched by the
genes found to be differentially up-regulated in (A) MCSP- and (B) ABCB5-enriched CTCs. Enriched
cellular hallmarks in CTCs are shown in green boxes, while genes shown in grey are those that were
not found enriched in this study but are known to be important for melanomagenesis. Canonical
pathway signalling is indicated by continuous arrows and dotted arrows indicates a previously
reported interaction.
Figure 4. Identification of genes specific to single melanoma tumour cells that are also up-regulated
in MCSP- and ABCB5-enriched CTC fractions. (A) Pivot plot comparing gene expression profiles of
single tumour cells and nonmalignant cells, from publicly available data [31], identified 847 genes that
are specifically expressed by single tumour cells (red triangle) and 196 genes specifically expressed
by single nonmalignant cells (black triangle). Comparison of these tumour-specific genes against the
genes found to be up-regulated in MCSP (B) and ABCB5 CTC fractions (C) identified, respectively,
11 and 10 genes that are commonly expressed by single melanoma tumours as well as by MCSP or
ABCB5 CTC fractions.
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Table 2. Enriched cellular hallmarks in MCSP CTC fractions from metastatic melanoma cases.
Gene Set Name (Hallmark) Number of Genes inOverlap k/K p-Value FDR q-Value Overlapped Genes
TNFA_SIGNALING_VIA_NFKB 20 0.1 3 × 10−21 1.5 × 10−19
IL1B, NAMPT, NFKBIA, TNFAIP6, ABCA1, TNFAIP3, G0S2, TRIB1,
NFIL3, SLC2A3, IRS2, SOCS3, GADD45B, SAT1, PLK2, BCL6, NR4A2,
CCNL1, BCL2A1, B4GALT5
INFLAMMATORY_RESPONSE 16 0.08 1.1 × 10−15 2.8 × 10−14 IL1B, NAMPT, NFKBIA, TNFAIP6, ABCA1, RAF1, ADM, HIF1A, CSF3R,AQP9, IL18RAP, MEFV, SLC31A2, FAR2, KCNJ2, PROK2
KRAS_SIGNALING_UP 9 0.045 3.3 × 10−7 5.5 × 10−6 IL1B, TNFAIP3, G0S2, TRIB1, CSF2RA, ARG1, LY96, CLEC4A, TLR8
COMPLEMENT 8 0.04 3.6 × 10−6 3.0 × 10−5 TNFAIP3, RAF1, PLSCR1, CDA, CR1, F5, GCA, ITGAM
HYPOXIA 8 0.04 3.6 × 10−6 3.0 × 10−5 TNFAIP3, NFIL3, SLC2A3, ADM, IRS2, DDIT3, EXT1, FOXO3
INTERFERON_GAMMA_RESPONSE 8 0.04 3.6 × 10−6 3.0 × 10−5 NAMPT, NFKBIA, TNFAIP6, TNFAIP3, HIF1A, EIF4E3, PLSCR1, SOCS3
IL2_STAT5_SIGNALING 7 0.035 3.5 × 10−5 2.2 × 10−4 NFIL3, SLC2A3, GADD45B, PLSCR1, IL1R2, NFKBIZ, WLS
MTORC1_SIGNALING 7 0.035 3.5 × 10−5 2.2 × 10−4 NAMPT, NFIL3, SLC2A3, DDIT3, IDI1, FAM129A, IFRD1
IL6_JAK_STAT3_SIGNALING 5 0.0575 4.6 × 10−5 2.6 × 10−4 IL1B, SOCS3, CSF3R, CSF2RA, IL1R2
BILE_ACID_METABOLISM 5 0.0446 1.5 × 10−4 7.7 × 10−4 ABCA1, AQP9, IDI1, ACSL1, SULT1B1
Table 3. Enriched cellular hallmarks in ABCB5 CTC fractions from metastatic melanoma cases.
Gene Set Name (Hallmark) Number of Genes inOverlap k/K p-Value FDR q-Value Overlapped Genes
EPITHELIAL_MESENCHYMAL_TRANSITION 8 0.04 4.7 × 10−7 2.3 × 10−5 VCAN, MYL9, PLOD2, LRP1, THBS1, FGF2, PTX3, CALU
APICAL_JUNCTION 7 0.035 6 × 10−6 1 × 10−6 VCAN, MYL9, INSIG1, ADAM9, SRC, VCL, RRAS
HEME_METABOLISM 7 0.035 6 × 10−6 1 × 10−6 H1F0, ENDOD1, BLVRA, CTNS, HEBP1, MARCH2, SNCA
ANDROGEN_RESPONSE 4 0.04 4 × 10−4 4.5 × 10−3 INSIG1, H1F0, GUCY1A3, ABCC4
ESTROGEN_RESPONSE_EARLY 5 0.025 6.3 × 10−4 4.5 × 10−3 ENDOD1, KLF10, MYOF, AMFR, ZNF185
KRAS_SIGNALING_UP0 5 0.025 6.3 × 10−4 4.5 × 10−3 GUCY1A3, TSPAN13, YRDC, EPB41L3, MMD
MTORC1_SIGNALING 5 0.025 6.3 × 10−4 4.5 × 10−3 PLOD2, INSIG1, DDIT3, STARD4, MLLT11
COAGULATION 4 0.029 1.3 × 10−3 8.1 × 10−3 LRP1, THBS1, ADAM9, SERPING1
COMPLEMENT 4 0.02 4.9 × 10−3 2.7 × 10−2 LRP1, ADAM9, SRC, SERPING1
PI3K_AKT_MTOR_SIGNALING 3 0.029 5.6 × 10−3 2.7 × 10−9 DDIT3, DUSP3, MAP2K6
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This approach identified a total of 11 and 10 genes (Table 4) expressed in single tumour cells
that were overexpressed in the MCSP- and ABCB5-enriched CTC fractions, respectively. Of note,
WIPI1 (WD repeat domain phosphoinositide-interacting protein 1) and DDIT3 (DNA damage inducible
transcript 3) were the only two genes found to be overexpressed in both CTC fractions. Additionally,
a total of 196 genes were also identified to be specifically expressed by the nonmalignant cells. However,
only two of those genes were also found to be up-regulated in either MCSP- or ABCB5-enriched
CTC fractions.
Table 4. Shared genes between CTC fractions and specifically expressed genes in single melanoma
tumour cells.
CTC Fraction Gene Symbols
MCSP CTC ST6GALNAC2, DDIT3, PLK2, LOXL4, CYSTM1,WIPI1, PYGL, GLUL, SAT1, SKP1, SEC31A
ABCB5 CTC CYB5R1, H1F0, DUSP3, DDIT3, CREG1, ENDOD1,CALU, WIPI1, TXN2, SNCA
3. Discussion
To improve cancer therapy, it is critical to target metastasizing cells. A better understanding
of the biology of CTCs and the molecular mechanisms dictating melanoma cell spreading offers a
potential avenue to inform treatment. Moreover, by understanding the biological heterogeneity of
CTCs, methods to identify CTC subpopulations that seed metastases and/or provide resistance to
treatment can be developed. Here, in this study, we report on CTC subpopulations expressing either
MCSP, a melanoma-associated marker [25], or ABCB5, a melanoma-initiating marker [28], and show
that they display distinct transcriptomic profiles. This study confirms the phenotypic and molecular
heterogeneity observed in melanoma CTCs [5,9–12,33] and highlights genes and cellular pathways
that may be associated with the biology of MCSP or ABCB5 CTC subtypes.
The most significant finding from this study is that, based on gene expression data, MCSP-
and ABCB5-enriched CTCs are two distinct cell subpopulations. This is based on the limited
overlap observed between the genes found to be up-regulated in MCSP and ABCB5 CTCs and the
different pathways prominently enriched in these two CTC-enriched fractions. MCSP is a melanocytic
membrane proteoglycan involved in melanomagenesis, tumour growth, motility, and tissue invasion
of melanoma cells through activation of integrin function, FAK (focal adhesion kinase) signalling,
ERK signalling, and matrix metalloproteinase 2 [25,34–37]. Because MCSP is expressed in over 90% of
melanomas [25], this cell surface proteoglycan has been used as a conventional marker for the capture
and detection of CTCs, but little is known of its efficacy in identifying CTCs or about the biology
of MCSP-positive CTCs [5,7–11,22–24]. Here, our gene set enrichment analysis (GSEA) performed
with genes found to be significantly up-regulated in the MCSP-enriched CTC fractions, showed that
the TNFA_SIGNALING_VIA_NFKB hallmark was most significantly enriched in this CTC-subtype.
Furthermore, IL2_STAT5_SIGNALING, MTORC1_SIGNALING, and IL6_JAK_STAT3_SIGNALING
were hallmarks of the MCSP-enriched CTC fractions. The enrichment of these cellular networks
in these CTC fractions is interesting as MCSP tumorigenic signalling depends on the activation of
SRC kinases, FAK, STAT transcription factors and apoptotic regulators including TP53, TOR and
JNK [26]. These findings indicate that MCSP CTCs are equipped with tumorigenic capabilities, such as
maintenance of cell survival, cell proliferation, and migration, as they travel through the bloodstream
(Figure 3). Nevertheless, the limited overlap in gene expression observed between single tumour
cells and these CTC fractions might indicate that these cellular networks might function differently
in CTCs in comparison to tissue-derived tumour cells. An in-depth understanding of MCSP-driven
signalling in the biology of MCSP-positive tumour cells and CTCs and its role in melanomagenesis
and metastasis demands further investigation.
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Contrary to MCSP-enriched CTC fractions, ABCB5-enriched CTC fractions showed a significant
enrichment of the epithelial mesenchymal transition and the apical junction hallmarks, which are
crucial steps in metastasis [38]. ABCB5, an ATP-binding cassette, is a melanoma ‘stem cell’
marker of a slow-cycling population of tumour cells with self-renewal, proliferation, differentiation,
and tumorigenicity capabilities [28–30]. Moreover, melanoma tumour cells expressing ABCB5 have
been found to escape chemotherapy and MAPK inhibition, possibly as a result of its drug-efflux
function [27,28]. The significant enrichment of EMT genes in ABCB5-enriched CTCs is interesting
since EMT is a process in melanoma by which the melanoma cells lose their melanocytic phenotype
and acquire a more invasive phenotype [39]. This is particularly important as, except for CALU,
the remaining seven EMT genes found to be up-regulated in ABCB5-enriched CTC fractions have
been previously associated with melanoma metastasis, invasion, and/or tumour growth. Previously,
ABCB5 expression has been associated with melanoma progression and resistance [28], yet it is
unclear how ABCB5 drives melanoma spreading. Recently, Yao, et al. [40] found that ABCB5 promotes
metastasis and invasion in breast cancer by up-regulating ZEB1 (zinc finger e-box binding homeobox 1),
an EMT-driving transcription factor that is also involved in melanoma EMT [39]. The significant
enrichment of the apical junction hallmark in ABCB5 CTCs is interesting as loss of cell polarity
represents a step towards EMT cancer [38]. It is interesting that enrichment of EMT and apical junction
hallmarks is found specifically in ABCB5 CTCs and suggests that both cellular processes may be key
in ABCB5 CTC biology, since ABCB5 indirectly activates WNT-IL8 signalling by negative regulation
of the WNT-repressor, WFDC1 [29]. Thus, ABCB5 CTCs might be enriched for EMT and apical
junction transcriptional programs (Figure 3B) via WNT signalling, which is known to regulate both
programs. Additionally, the significant enrichment of melanoma EMT-involved pathways, such as
the MTORC1_SIGNALING and PI3K_AKT_MTOR_SIGNALING hallmarks in these CTC fractions,
suggests an invasive transcriptional programming of ABCB5 CTCs [39] (Figure 3B). The finding
of PI3K/AKT in ABCB5 CTCs is interesting as the PI3K-AKT signalling pathway has been shown
to regulate the quiescence of melanoma stem-cells characterised by high ABCB5 expression [41].
The presence of an EMT signature in the ABCB5 CTC fractions indicates that activation of this
signature might play a critical role either in the migration of these CTCs from the tumour or in
their ability to seed new tumours. Since ABCB5 is a common marker in CTCs but expressed only
in rare cell subpopulations in matched melanoma tumour tissues [5], it is possible that rare tumour
subpopulations, through ABCB5 expression, might acquire invasive capabilities via EMT activation.
In this study, we observed that MCSP and ABCB5 CTC fractions had 11 and 10 genes commonly
expressed with single melanoma tumour cells, respectively. The limited overlap between gene
expression profiles of single tumour cells and both CTC fractions might reflect differences in the
transcriptional programming of CTCs and tumours. Interestingly, only WIPI1 and DDIT3 were shared
between both CTC fractions and single melanoma cells. WIPI1 has been involved in melanosome
formation and regulation of melanogenic enzymes, such as MITF and its targets, via negative regulation
of TORC1 signalling [42]. Additionally, WIPI1 was identified as the signature gene able to differentiate
primary melanomas from normal skin [43]. However, we observed upregulation of WIPI1 as well as
of genes involved in mTORC1 signalling in both fractions, with no evidence of MITF transcriptional
programming. Altogether, this suggests dysregulation of these signalling pathways in melanoma
and CTC biology. Thus, further investigation on the role of WIPI1 and mTORC1 upregulation and
signalling in CTC biology is required. On the other hand, DDIT3, a mediator of endoplasmic reticulum
stress-mediated apoptosis [44], has not been implicated in melanoma biology to date. However, DDIT3
was up-regulated as a result of the apoptotic activity triggered by the compound HA15 in melanoma
cell lines [45], as was SEC31A, [45] a gene found up-regulated in MCSP CTC fractions, Altogether,
the role of WIPI1 and DDIT3 may indicate common molecular mechanisms in CTC biology. It is critical
to understand such mechanisms in order to determine the changes in transcriptional programming
that tumour cells undergo to become CTCs.
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With regard to the genes specifically up-regulated in the MCSP CTC fraction, the majority have
been involved in metastasis (LOXL4, ST6GALNAC2, PYGL), tumour growth (PLK2, CYSTM1, GLUL),
and/or melanoma biology (SEC31A, WIPI1, SKP1) [42,43,45–53]. Similarly, the up-regulated genes in
the ABCB5 CTC fractions were involved in metastasis (CALU, CYB5R1, DUSP3, CREG1, ENDOD1),
tumour growth, and/or melanoma biology (H1F0, SCNA, WIPI1, TXN2) [42,43,54–60]. These findings
support the suggestion that these two CTC subpopulations exhibit different gene expression patterns
but similar molecular mechanisms underlying their biology.
By interrogating the transcriptome of MCSP- and ABCB5-enriched CTCs, we herein
provide novel evidence supporting the transcriptional heterogeneity within and amongst CTC
subpopulations [5,10–12,24,33]. In addition, this study provides an insight into the molecular
mechanisms underlying the biology of MCSP and ABCB5 CTCs. However, based on the low detection
rates of CTCs, described here (42%) and elsewhere (40–87%) [5,7,9,11,12,21,33], it is likely that other
CTC subpopulations currently remain undetected. Unbiased isolation and detection methods are
required in order to capture the true heterogeneity of CTCs. Such studies will provide CTC subtype
specific markers other than MCSP and ABCB5 and will provide a better understanding of the biology
of specific CTC subtypes as well as their association with melanoma biology. In addition, analysis
of pure CTCs fractions or of single CTCs is needed to ascertain their transcriptional programming
without being confounded by the background of white blood cells.
4. Methods
4.1. Patient Recruitment and Blood Collection
Metastatic melanoma patients were enrolled in the study at Sir Charles Gardner Hospital and
Royal Perth Hospital in Perth, Western Australia. Written informed consent was obtained from
all patients. The study was approved by the Human Research Ethics Committees of Edith Cowan
University (No. 11543) and Sir Charles Gairdner Hospital (No. 2013-246). Peripheral blood samples
from healthy volunteers and patients were collected by phlebotomists into 4 mL BD Vacutainer® K2
EDTA tubes (BD Life Sciences, Franklin Lakes, NJ, USA), from which the first few millilitres were
discarded to avoid epithelial contamination, then refrigerated at 4 ◦C and analysed within 24 h.
4.2. CTC Enrichment and Nucleic Acid Extraction
CTCs were enriched as previously described [10]. In summary, whole blood was treated with
red blood cell lysing buffer and the remaining cells were incubated with immunomagnetic beads
coated with antibodies against MCSP (clone 9.2.27, BD Biosciences, Franklin Lakes, NJ, USA) or ABCB5
(clone 3C2-1D12) [28]. After washing, RNA was extracted from these CTC fractions using previously
described methodologies [12,32].
4.3. RT-PCR
Extracted RNA (6 µL) was used for cDNA preparation using the SuperScript® VILO™ cDNA
Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA) followed by a TaqMan® PreAmp Master
Mix Kit (Thermo Fisher Scientific). The presence of transcripts for melanoma genes MLANA, TYR,
MAGEA3, PAX3, and ABCB5 was determined using TaqMan® probes in a ViiA 7 Real-time instrument
(Thermo Fisher Scientific). Detection of 18S rRNA was used as an endogenous control gene [12,32].
4.4. Microarray
RNA quantity and quality were analysed with a Pico Bioanalyzer chip (Agilent Technologies,
Santa Clara, CA, USA). Samples were prepared using the NuGEN Pico WTA kit (NuGEN Technologies,
San Carlos, CA, USA). Labelling and hybridization according to the Affymetrix® GeneChip® genome
2.0 ST array protocol (Affymetrix, Santa Clara, CA, USA) was performed at the Ramaciotti Centre for
Gene Function Analysis (University of New South Wales, Sydney, Australia).
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4.5. Microarray Data Analysis
Microarray data were analysed using Partek Genomics Suite software version 6.5 (Partek
Inc., St. Louis, MO, USA). Raw data were normalised using the robust multi-array average
(RMA) normalisation approach. The data fulfil the MIAME (Minimum Information About a
Microarray Experiment) guidelines and have been uploaded into the National Center for Biotechnology
Information (NCBI)’s GEO database (accession number GSE113166). The differentially expressed gene
list was generated with ANOVA p < 0.05 and fold difference 2 vs. respective controls in either cell type
(MSCP or ABCB5 CTCs). Unsupervised two-dimensional hierarchical clustering with complete linkage
was performed on differentially expressed genes using Spearman’s correlation as a similarity matrix.
4.6. Gene Set Enrichment Analysis (GSEA)
Genes found to be significantly up-regulated (≥2-fold change and p < 0.05) in the MCSP-enriched
and ABCB5-enriched CTC fractions were contrasted with collections from the Molecular Signatures
Database (MSigDB v6.0; Broad Institute, Boston, Massachusetts, USA) [61]. Particularly, we used the
Hallmark gene set collection in order to reduce redundancy of the pathways being enriched and obtain
more biologically meaningful results [62]. For each CTC fraction, the top ten hallmark gene sets with a
p-value below 0.01 and a false discovery rate (FDR) q-value below 0.01 were obtained and analysed.
4.7. Identification of Tumour-Derived Genes in the MCSP- and ABCB5-Enriched Fractions
To identify genes that are commonly expressed between melanoma tumours and the MCSP- and
ABCB5-enriched CTC fractions, we used publicly available single cell RNAseq data (Gene Expression
Omnibus series no. GSE72056) from melanoma tumours. This dataset comprises RNAseq data of
1257 single tumour cells and 3256 single nonmalignant cells from a total of 19 melanoma tumours [31].
Visualisation and analysis of this single cell RNAseq dataset were performed on the SeqGeq™ platform
(v1.0.1; FlowJo®, LLC, Ashland, Oregon). Firstly, genes that were more specifically expressed by
melanoma tumour cells than by nonmalignant cells were identified by comparing the gene expression
profiles of all single tumour cells and nonmalignant cells followed by gating them out in a pivot plot.
In this plot, the sum of the expression levels for each gene of a population of interest is normalised to
the maximum each gene can be expressed in the comparative population. Thus, a gene that is closer to
an axis is more expressed by the population the axis belongs to. Secondly, these melanoma-specific
genes were contrasted to the list of genes found to be up-regulated in the MCSP- and ABCB5-enriched
CTC fractions in order to detect commonly expressed genes between melanoma tumour cells and
CTC fractions.
5. Conclusions
Overall, gene expression profiling of MCSP-enriched and ABCB5-enriched CTCs provide evidence
that MCSP- and ABCB5-enriched CTCs are two transcriptionally distinct CTC subpopulations with
MCSP CTCs, the more melanocytic cell subpopulation, whilst ABCB5 CTCs may be a more invasive
cell subpopulation as a result of their EMT profiles. This study is the first to characterise two different
melanoma CTC subpopulations, unveiling the differences in their transcriptional programs and
suggesting distinct biological pathways activated in these cells. These findings will lead to further
studies to determine the biology and role of these CTC subpopulations in melanoma metastasis.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/2/157/s1,
Figure S1. Expression profiling of 5 melanoma-specific genes in CTC fractions selected for whole genome gene
expression analysis. Six melanoma and six healthy donor samples were enriched targeting either MCSP or
ABCB5 markers. Gene expression was assessed by qRT-PCR and Ct values are shown for each sample and each
gene (U = undetected transcript levels). The 18S rRNA gene was used as an endogenous control. Results have
been shaded with darker tones indicating lower Ct values, Table S1: List of genes differentially regulated in
MCSP CTCs fraction between controls and patients, Table S2: List of genes differentially regulated in ABCB5
CTCs fraction between controls and patients, Table S3: Shared genes between MCSP- and ABCB5-enriched
MelCTC fractions, Table S4: Genes specifically upregulated in MCSP-enriched MelCTC fractions, Table S5: Genes
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specifically upregulated in ABCB5-enriched MelCTC fractions, Table S6: Genes specifically expressed by single
melanoma tumour cells.
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